Chonnam Med J.  2004 Dec;40(4):203-207.

Complications of Intravitreal Injection with Triamcinolone Acetonide

Affiliations
  • 1Department of Ophthalmology, Chonnam National University Medical School, Korea. msseo@chonnam.ac.kr
  • 2Chonnam National University Research Institute of Medical Sciences, Gwangju, Korea.

Abstract

To evaluate the complications of intravitreal injection with triamcinolone acetonide (TA), we retro- spectively analyzed the clinical records of 103 eyes in 96 patients who were intravitreally injected with TA 0.1 ml (4.0 mg) and followed-up over 3 months. Mean age was 54.6 years. 50 patients (59 eyes) were males. The causative diseases were diabetic macular edema in 78 eyes (75.7%) of 71 patients, retinal vein occlusion in 12 eyes (11.7%) of 12 patients, uveitis in 6 eyes (5.8%) of 6 patients, age-related macular degeneration in 3 eyes (2.9%) of 3 patients, pseudophakic macular edema in 3 eyes (2.9%) of 3 patients and hypertensive retinopathy in 1 eye (1.0%) of 1 patient. Complications were increased intraocular pressure (IOP) in 43 eyes, pseudohypopyon in 2 eyes and intralenticular TA in 1 eye. There was no endophthalmitis. Mean time of IOP elevation was 6.9 weeks after the procedure. In most cases, increased IOP was controlled with topical antiglaucomatous eyedrops. Intravitreal injection of TA is a relatively safe procedure. However, special precaution should be taken for the complications such as increased IOP.

Keyword

Intraocular pressure; Intravitreal injection; Triamcinolone acetonide

MeSH Terms

Endophthalmitis
Humans
Hypertensive Retinopathy
Intraocular Pressure
Intravitreal Injections*
Macular Degeneration
Macular Edema
Male
Ophthalmic Solutions
Retinal Vein Occlusion
Triamcinolone Acetonide*
Triamcinolone*
Uveitis
Ophthalmic Solutions
Triamcinolone
Triamcinolone Acetonide
Full Text Links
  • CMJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr